[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500111":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":38,"locations":47,"responsibleParty":99,"collaborators":25,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":25,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":25,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University Hospital, Tours","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with acute leukemias","ACTIVE_COMPARATOR","Children with acute lymphoid leukemia B, acute lymphoid leukemia -T or acute myeloid leukemia",[13],"Procedure: Biological sampling in patients",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group","Children without blood diseases",[18],"Procedure: Biological sampling in control patients",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Biological sampling in patients","blood and bone marrow samples from patients with Acute Leulemia.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Biological sampling in control patients","blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).",[15],[31,35],{"name":32,"affiliation":33,"role":34},"Olivier HERAULT, MD-PhD","University Hospital of TOURS","STUDY_DIRECTOR",{"name":36,"affiliation":33,"role":37},"Julien LEJEUNE, MD-PhD","PRINCIPAL_INVESTIGATOR",[39,43],{"name":32,"role":40,"phone":41,"phoneExt":25,"email":42},"CONTACT","+33(0)234378902","olivier.herault@univ-tours.fr",{"name":44,"role":40,"phone":45,"phoneExt":25,"email":46},"Wiebe de JONG, MSc","+33(0)247474680","w.dejong@chu-tours.fr",[48,65,88],{"facility":49,"status":50,"city":51,"state":25,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Service d'hématologie biologique-CHRU TOURS","NOT_YET_RECRUITING","Tours","37044","France","FR",{"type":56,"coordinates":57},"Point",[58,59],0.70398,47.39484,{"lat":59,"lon":58},[62,64],{"name":32,"role":40,"phone":63,"phoneExt":25,"email":42},"+33(0)247474721",{"name":32,"role":37,"phone":25,"phoneExt":25,"email":25},{"facility":66,"status":67,"city":51,"state":25,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Service d'onco-hématologie pédiatrique -CHRU Tours","RECRUITING",{"type":56,"coordinates":69},[58,59],{"lat":59,"lon":58},[72,74,75,78,80,82,84,86],{"name":36,"role":40,"phone":25,"phoneExt":25,"email":73},"j.lejeune@chu-tours.fr",{"name":36,"role":37,"phone":25,"phoneExt":25,"email":25},{"name":76,"role":77,"phone":25,"phoneExt":25,"email":25},"Emmanuel Gyan, MD-PhD","SUB_INVESTIGATOR",{"name":79,"role":77,"phone":25,"phoneExt":25,"email":25},"Pascale Blouin, MD",{"name":81,"role":77,"phone":25,"phoneExt":25,"email":25},"Anne Jourdain, MD",{"name":83,"role":77,"phone":25,"phoneExt":25,"email":25},"Marion Gillibert-Yvert, MD",{"name":85,"role":77,"phone":25,"phoneExt":25,"email":25},"Jill Serre, MD",{"name":87,"role":77,"phone":25,"phoneExt":25,"email":25},"Léa Bosdure, MD",{"facility":89,"status":67,"city":51,"state":25,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"Service de chirurgie orthopédique pédiatrique -CHRU TOURS",{"type":56,"coordinates":91},[58,59],{"lat":59,"lon":58},[94,98],{"name":95,"role":40,"phone":96,"phoneExt":25,"email":97},"Thierry ODENT, MD-PhD","+33(0)247473822","t.odent@chu-tours.fr",{"name":95,"role":37,"phone":25,"phoneExt":25,"email":25},{"type":100,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100500111","study-of-the-medullary-microenvironment-in-acute-childhood-leukemia-100500111",false,"NCT05792007","Study of the Medullary Microenvironment in Acute Childhood Leukemia","Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant","MILA","Inclusion Criteria:\n\n* for patients with AL:\n\n  1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis\n  2. Not having received prior hematological treatment\n  3. Aged 1 to 15 years old\n  4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.\n  5. Affiliated patient or beneficiary of a social security scheme.\n* Control group patients:\n\n  1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).\n  2. Aged between 1 and 15 years old.\n  3. Having no pathology of hematological origin.\n  4. Not having received any treatment that could interfere with the functioning of the bone marrow.\n  5. Whose 2 parents or the holder of parental authority have signed a consent enlightened.\n  6. Affiliated patient or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* for patients with AL:\n\n  1. Patient under 1 year old and over 15 years old.\n  2. Contraindication to myelogram.\n  3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.\n  4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia.\n  5. Having received prior hematological treatments.\n  6. Parents with physical or mental condition not allowing to understand the informed consent.\n* Control group patients\n\n  1. Patient under 1 year old and over 15 years old.\n  2. Having an underlying haematological pathology.\n  3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority.\n  4. Having received prior hematological treatments.\n  5. Parents with physical or mental condition not allowing to understand informed consent.",true,"ALL","1 Year","15 Years",{"count":114,"type":115},40,"ESTIMATED","INTERVENTIONAL",[118],"NA","Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and\u002For progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.",[121,122],"Acute Lymphoid Leukemia","Acute Myeloid Leukemia in Children","2025-11-18",{"date":125,"type":126},"2025-11-24","ACTUAL",{"date":128,"type":126},"2023-10-26",{"date":130,"type":115},"2028-10-24",{"name":5,"class":6},3]